We then calculated individual EBNA-derived and CNS-derived peptide-specific CD19+ B cell, CD4+ T cell, and CD8+ T cell levels that, independently of the EBNA- and CNS-derived peptide-specific antibody titers, were associated with an increased risk for MS (Supplemental Table 3). This evidence concerns the gene CD19 and myeloid sarcoma.